Revance Therapeutics Announces FDA Approval Of DAXXIFY For Treatment Of Cervical Dystonia On August 11, 2023
Portfolio Pulse from Benzinga Newsdesk
Revance Therapeutics has received FDA approval for DAXXIFY, a treatment for cervical dystonia, according to an SEC filing. The approval was announced on August 11, 2023.
August 14, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Revance Therapeutics' stock may see positive movement following the FDA approval of its treatment for cervical dystonia, DAXXIFY.
FDA approval of a new drug is a significant milestone for any pharmaceutical company. This approval could lead to increased revenues for Revance Therapeutics, which may positively impact its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100